Skip to Content

ChondroCelect

Active Substance: characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins
Common Name: characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins
ATC Code: M09AX02
Marketing Authorisation Holder: TiGenix N.V.
Active Substance: characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins
Status: Withdrawn
Authorisation Date: 2009-10-05
Therapeutic Area: Cartilage Diseases
Pharmacotherapeutic Group: Other drugs for disorders of the musculo-skeletal system

Therapeutic Indication

Repair of single symptomatic cartilage defects of the femoral condyle of the knee (International Cartilage Repair Society [ICRS] grade III or IV) in adults.

Concomitant asymptomatic cartilage lesions (ICRS grade I or II) might be present. Demonstration of efficacy is based on a randomised controlled trial evaluating the efficacy of Chondrocelect in patients with lesions between 1 and 5 cm².

The marketing authorisation for Chondrocelect has been withdrawn at the request of the marketing-authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide